2-(三氟甲基)苄溴结构式
|
常用名 | 2-(三氟甲基)苄溴 | 英文名 | 1-(Bromomethyl)-2-(trifluoromethyl)benzene |
|---|---|---|---|---|
| CAS号 | 395-44-8 | 分子量 | 239.032 | |
| 密度 | 1.6±0.1 g/cm3 | 沸点 | 201.9±0.0 °C at 760 mmHg | |
| 分子式 | C8H6BrF3 | 熔点 | 34-35ºC | |
| MSDS | 中文版 美版 | 闪点 | 83.3±0.0 °C | |
| 符号 |
GHS05 |
信号词 | Danger |
|
Distributed Drug Discovery, Part 3: using D(3) methodology to synthesize analogs of an anti-melanoma compound.
J. Comb. Chem. 11(1) , 34-43, (2009) For the successful implementation of Distributed Drug Discovery (D(3)) (outlined in the accompanying Perspective), students, in the course of their educational laboratories, must be able to reproducibly make new, high quality, molecules with potential for bio... |
|
|
Distributed Drug Discovery, Part 2: global rehearsal of alkylating agents for the synthesis of resin-bound unnatural amino acids and virtual D(3) catalog construction.
J. Comb. Chem. 11 , 14-33, (2009) Distributed Drug Discovery (D(3)) proposes solving large drug discovery problems by breaking them into smaller units for processing at multiple sites. A key component of the synthetic and computational stages of D(3) is the global rehearsal of prospective rea... |
